AstraZeneca and Ironwood Pharmaceuticals have entered an agreement to co-develop and co-commercialize Ironwood’s linaclotide in China. Linaclotide, an aguanylate cyclase-C (GC-C) agonist, received FDA approval in August. Ironwood has also filed a clinical trial application with the SFDA in China for a Phase III trial to assess safety and efficacy of linaclotide in irritable bowel syndrome with constipation (IBS-C). The two companies are jointly responsible for strategic oversight of the devel...